Search results

• Leveraging expertise in UV filters for Asian markets

  There are over three million cases of skin cancer globally each year, responsible for tens of thousands of deaths. Our range of sunscreens meets a clear need and is an important pillar of our sustainability Commitment to be People Positive by 2030.

• Human Performance programme

  Our behavioural safety improvement programmes were standardised into a Group-wide Behavioural Safety Observation programme, implemented across all manufacturing sites since 2015.

• Media coverage Page Summary Title

  Media coverage Page Summary Description

• Reforestation

  Revitalising ecosystems, improving biodiversity and creating social and economic benefits for local communities.

• Investor seminar on our Life Sciences sector

  7 October 2019: Senior members of our management team provided a comprehensive overview of the Life Sciences sector, with a particular focus on our Health Care business.

• Site visit to Sederma Beauty Actives business in France

  17-18 March 2016: Croda International plc hosted a Capital Markets Event for analysts and investors at its Sederma facility near Versailles, France.

• Consumer Care business review

  Discover how Consumer Care is reinvigorating Beauty and enabling continued growth in Fragrances & Flavours. Exploring innovation, market trends, and strategic growth driving performance in this year’s annual report business review.

• 2025 Annual Report

  Croda’s 2025 Annual Report allows you to explore our financial performance, strategic progress, sustainability highlights, and innovation driving long-term growth.

• People Positive

  By 2030, we will be People Positive.

• Supplying delivery systems to help prevent cardiovascular disease

  Nucleic acid-based therapies are the next big blockbuster drug class opening up exciting applications such as gene editing, where a patient’s genetic material can be modified to correct a disorder.

• Chairs statement 2025

  A message from the Chair, Danuta Gray, highlighting the company’s performance, strategic progress, governance priorities, and outlook for sustainable growth in the year ahead.

• Supporting the next generation of therapeutic vaccines

  Vaccine adjuvants are used to enhance immune response to an antigen, improving the overall efficacy of the vaccine and increasing protection against the target disease.

• Chief Executive's Statement 2025

  An overview from Steve Foots, our Chief Executive, outlining the year’s key achievements, business performance, strategic priorities, and future outlook for growth and innovation.

• Our markets

  We develop and supply innovative high-value ingredients that are typically included at low inclusion levels and offer critical functionality to our customers formulations. We are united by our Purpose of using Smart science to improve lives™, with our ingredients delivering a positive impact in all our markets.

• Environmental, Social and Governance (ESG)

  Useful links to further information on our environmental, governance and social impact.

• Croda announces brand evolution to mark centenary year animation Page Summary Title

  Croda announces brand evolution to mark centenary year animation Page Summary Description

• Key Performance Indicators

  Explore Croda’s key performance indicators for 2025, highlighting progress across financial performance, sustainability and strategic priorities.

• Bringing anti-ageing benefits to make-up

  Developed through one of our Smart Partnerships, Majestem® Drypure™ from our beauty actives business, Sederma, brings anti-ageing and environmental protection benefits to make-up.

• Danuta Gray, Chair's Letter 2024

  The Board and shareholders are aligned that the Company’s priorities should be execution and operational delivery to grow earnings and improve returns on invested capital.

• Steve Foots, Group Chief Executive Letter

  We are focused on delivery and modernisation, ensuring rigorous cost discipline and driving operational efficiencies to continue our long record of strong performance.